SN1N Stock Chart & Stats
$256.55
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$256.55 - $256.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$223.04B
Enterprise Value$12.80K
Total Cash (Recent Filing)$557.20M
Total Debt (Recent Filing)$3.33B
Price to Earnings (P/E)20.5
Beta0.03
Next Earnings
Aug 04, 2026EPS Estimate
8.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding840,515,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$329.06Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthMaterial FCF improvement (840m, +52.5%) strengthens long-term financial flexibility. Higher recurring cash enables sustained R&D, capital investment, dividends and buybacks, reduces reliance on external financing for M&A and supports resilience through cyclical healthcare demand.
Innovation-led RevenueA heavy share of growth from recent launches and a pipeline of 16 planned 2026 products indicates durable product-driven expansion. This supports sustainable market share gains, recurring consumable sales and higher lifetime customer value versus relying on legacy portfolios.
Margin Expansion & EfficiencyConsistent margin improvement driven by operating leverage and cost-savings programs points to stronger earnings power. Cumulative efficiency savings and better gross margin underpin sustainable profitability and improved ROIC potential over the medium term.
Bears Say
China VBP PressureVolume‑based procurement (VBP) is a structural policy change that compresses pricing and margins in China. Even if China is a small sales share, persistent procurement reforms force strategic adjustments, pricing pressure and could constrain long‑term growth from that market.
Reimbursement Risk In Wound CareRegulatory reimbursement shifts are a durable demand and margin risk for Advanced Wound Management. Reduced physician office volumes and lower reimbursement can permanently shrink addressable revenue unless mitigated by new product innovation or channel repositioning.
Inventory Write-down & RestructuringA large write-down from SKU rationalization signals structural portfolio transition and execution risk. While aimed at simplification, it reduces near-term asset quality, may disrupt supply/physician availability, and adds restructuring costs that can pressure returns until benefits are realized.
SN1N FAQ
What was Smith & Nephew (UK)’s price range in the past 12 months?
Smith & Nephew (UK) lowest stock price was $256.55 and its highest was $256.55 in the past 12 months.
What is Smith & Nephew (UK)’s market cap?
Smith & Nephew (UK)’s market cap is $223.04B.
When is Smith & Nephew (UK)’s upcoming earnings report date?
Smith & Nephew (UK)’s upcoming earnings report date is Aug 04, 2026 which is in 9 days.
How were Smith & Nephew (UK)’s earnings last quarter?
Smith & Nephew (UK) released its earnings results on Mar 02, 2026. The company reported $10.33 earnings per share for the quarter, beating the consensus estimate of $10.12 by $0.21.
Is Smith & Nephew (UK) overvalued?
According to Wall Street analysts Smith & Nephew (UK)’s price is currently Undervalued.
Does Smith & Nephew (UK) pay dividends?
Smith & Nephew (UK) does not currently pay dividends.
What is Smith & Nephew (UK)’s EPS estimate?
Smith & Nephew (UK)’s EPS estimate is 8.23.
How many shares outstanding does Smith & Nephew (UK) have?
Smith & Nephew (UK) has 840,515,800 shares outstanding.
What happened to Smith & Nephew (UK)’s price movement after its last earnings report?
Smith & Nephew (UK) reported an EPS of $10.33 in its last earnings report, beating expectations of $10.12. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Smith & Nephew (UK)?
Currently, no hedge funds are holding shares in MX:SN1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$329.06 (― Downside)
$329.06 (― Downside)
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.16%
12-Months-Change
Fundamentals
Return on Equity
2.43%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Smith & Nephew (UK)
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
SN1N Stock 12 Month Forecast
Average Price Target
$329.06